Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF

被引：21

作者：

Delaugerre, C

Roudiere, L

Peytavin, G

Rouzioux, C

Viard, JP

Chaix, ML

机构：

[1] Hop Necker Enfants Malad, Dept Virol, F-75015 Paris, France

[2] Hop Necker Enfants Malad, Dept Infect Dis, F-75015 Paris, France

[3] Hop Bichat Claude Bernard, Dept Pharmacol, F-75877 Paris, France

来源：

JOURNAL OF CLINICAL VIROLOGY | 2005年 / 32卷 / 03期

关键词：

HIV-1; tenofovir; resistance pattern; K65R; K70E; virologic failure;

D O I：

10.1016/j.jcv.2004.05.020

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The human immunodeficiency virus type 1 (HIV-1) resistance profile, K65R, K70E and M184V, on reverse transcriptase gene was associated with the virologic rebound consecutively to the switch of lopinavir/r to tenofovir DF in a stable regimen with nucleoside backbone of abacavir, lamivudine and didanosine. The high selective pressure on the same resistance pathway was probably associated with the loss of antiviral potency, even in well-controlled patient. (c) 2004 Elsevier B.V. All rights reserved.

引用

收藏

页码：241 / 244

页数：4

相关论文

共 27 条

[1] Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro [J].

Cherrington, JM ;

Mulato, AS ;

Fuller, MD ;

Chen, MS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2212-2216

[2] Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy [J].

DeAntoni, A ;

Foli, A ;

Lisziewicz, J ;

Lori, F .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) :899-903

[3]

FARTHING C, 2003, P 2 INT AIDS SOC C P

[4]

GALLANT J, 2003, P 43 INT C ANT AG CH

[5] A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation [J].

García-Lerma, JG ;

MacInnes, H ;

Bennett, D ;

Reid, P ;

Nidtha, S ;

Weinstock, H ;

Kaplan, JE ;

Heneine, W .

JOURNAL OF VIROLOGY, 2003, 77 (10) :5685-5693

[6] IDENTIFICATION OF A MUTATION AT CODON-65 IN THE IKKK MOTIF OF REVERSE-TRANSCRIPTASE THAT ENCODES HUMAN-IMMUNODEFICIENCY-VIRUS RESISTANCE TO 2',3'-DIDEOXYCYTIDINE AND 2',3'-DIDEOXY-3'-THIACYTIDINE [J].

GU, ZX ;

GAO, Q ;

FANG, HS ;

SALOMON, H ;

PARNIAK, MA ;

GOLDBERG, E ;

CAMERON, J ;

WAINBERG, MA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :275-281

[7] Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression [J].

Hoogewerf, M ;

Regez, RM ;

Schouten, WEM ;

Weigel, HM ;

Frissen, PHJ ;

Brinkman, K .

LANCET, 2003, 362 (9400) :1979-1980

[8]

JEMSEK J, 2004, P 11 C RETR OPP INF

[9]

LANDMAN R, 2004, P 11 C RETR OPP INF

[10] Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses [J].

Margot, NA ;

Isaacson, E ;

McGowan, I ;

Cheng, A ;

Miller, MD .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (01) :15-21